NasdaqGM - Delayed Quote USD

Aura Biosciences, Inc. (AURA)

7.10 -0.12 (-1.66%)
At close: April 24 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 895.16k -- 1973
Ms. Julie B. Feder CFO, Secretary & Treasurer 604.2k -- 1970
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer -- -- 1962
Mr. Patrick Nealon Senior Vice President of Clinical Development Operations -- -- --
Dr. Bruce Brown M.D. Senior VP & Therapeutic Area Head of Urologic Oncology -- -- --
Dr. Anthony Daniels M.D. Therapeutic Area Head of Ocular Oncology -- -- --
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs & Quality -- -- --
Dr. Jill J. Hopkins M.D. Chief Medical Officer & President of Research and Development -- -- 1965

Aura Biosciences, Inc.

80 Guest Street
5th Floor
Boston, MA 02135
United States
617 500 8864 https://www.aurabiosciences.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
88

Description

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Corporate Governance

Aura Biosciences, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024 - May 10, 2024
Aura Biosciences, Inc. Earnings Call

Related Tickers

RLAY Relay Therapeutics, Inc.
6.35
+7.63%
 
TNGX Tango Therapeutics, Inc.
7.76
-0.13%
 
TRDA Entrada Therapeutics, Inc.
12.43
-3.57%
 
DSGN Design Therapeutics, Inc.
3.6500
-0.27%
 
IMVT Immunovant, Inc.
28.80
+0.66%
 
GLPG Galapagos NV
28.77
-2.31%
 
AVTE Aerovate Therapeutics, Inc.
21.20
-8.70%
 
INZY Inozyme Pharma, Inc.
4.4000
0.00%
 
REPL Replimune Group, Inc.
6.33
-1.40%
 
AVBP ArriVent BioPharma, Inc.
15.30
-2.98%